Our purpose was to project and compare clinical and quality-adjusted life year (QALY) outcomes of adjuvant radiotherapy (ART) versus salvage RT (SRT) after radical prostatectomy for men with locally advanced prostate cancer. We constructed a Markov model to simulate the randomized studies of observation versus ART, assuming 75% of observation patients would receive SRT at PSA recurrence. Transition probabilities and utility inputs were drawn from randomized trials of ART and cohort studies of SRT. We projected 10-year PSA recurrence-free survival, metastasis-free survival and overall survival. We found that observation with selective SRT yielded slightly worse outcomes than ART for post-RT PSA recurrence-free survival (47 and 52%), metastasis-free survival (69 and 70%) and overall survival (72 and 73%). Findings were robust to sensitivity analyses. After adjusting for the disutility of RT, observation plus SRT yielded better QALYs at 10 years than ART (6.80 and 6.13 QALYs). Thus, observation plus SRT may be optimal for men likely to comply with surveillance who wish to minimize side effects of the treatment. These findings reflect outcomes for the average patient given the current level of evidence and are meant to help inform current decision-making as we await future clinical studies of comparative effectiveness. Given a negative postoperative PSA, the 5-year PSA recurrence risk in such men varies from 2% in a 65-yearold man with preoperative PSA of 4 ng ml À1 , Gleason grade 3 þ 3 tumor with only one pathological findings of locally advanced disease to 70% in a 65-year-old man with preoperative PSA of 10 ng ml À1 , Gleason grade 4 þ 4 tumor with positive surgical margins, extracapsular extension and seminal vesicle invasion.
Introduction
Approximately one-third of men undergoing radical prostatectomy have locally advanced prostate cancer (PC), characterized by positive surgical margins, extracapsular extension and/or seminal vesicle invasion. 1 Given a negative postoperative PSA, the 5-year PSA recurrence risk in such men varies from 2% in a 65-yearold man with preoperative PSA of 4 ng ml À1 , Gleason grade 3 þ 3 tumor with only one pathological findings of locally advanced disease to 70% in a 65-year-old man with preoperative PSA of 10 ng ml À1 , Gleason grade 4 þ 4 tumor with positive surgical margins, extracapsular extension and seminal vesicle invasion. 2 In such men, postoperative pelvic radiotherapy (RT) significantly improves disease control [3] [4] [5] [6] [7] but has side effects. 8 For men with locally advanced PC, RT can be administered as either adjuvant RT (ART, given postoperatively to prevent recurrence) or salvage RT (SRT), given after a period of initial observation, if/when local recurrence is suspected. Three randomized trials of men with locally advanced PC demonstrated a 5-year PSA recurrence probability following prostatectomy of about 50% for men assigned to observation and 25% after ART. 3, 6, 7 One trial also showed a statistically significant difference in metastasis (hazards ratio 0.71, 95% confidence interval 0.54-0.94) and overall survival (hazards ratio 0.72, 95% confidence interval 0.55-0.96). 9 However, results for metastasis and death were possibly biased: only 32% of men with PSA recurrence on observation received SRT and of those only 55% received it early (i.e., at the first signs of PSA recurrence) when SRT is most effective. Moreover, the design biased against observation-in this group, the endpoint was pre-SRT PSA recurrence, not post-SRT PSA recurrence. There are no randomized trials of SRT, but several cohort studies 4, 5, [10] [11] [12] [13] [14] [15] [16] [17] suggest improved metastasis-free and overall survival. 17 Given the current state of knowledge, the ideal comparative effectiveness trial would randomize men with locally advanced PC at prostatectomy to either (1) ART or (2) observation plus early SRT. Such a trial is underway, but will take over a decade to recruit enough patients (48000) and evaluate clinically important endpoints. 18 Some argue that for these reasons, the ART versus SRT question is unlikely to ever be settled by a clinical trial. 19 To aid current patient-provider discussions, we used decision analysis to synthesize the current evidence and project outcomes over a 10-year time horizon: post-RT PSA recurrence-free survival, metastasis-free survival, overall survival and quality-adjusted life years (QALYs).
Materials and methods

Data sources
Articles for inclusion were drawn from a systematic review of radiation after radical prostatectomy published in 2008, 20 as well as a PubMed search with MeSH term 'prostate cancer' and the subheading 'radiotherapy', as well as the free text terms 'prostate cancer and salvage radiation' and 'prostate cancer and adjuvant radiation'. We used published results from three randomized trials of initial observation versus ART-the Southwestern Oncology Group (SWOG), 6, 9 European Organization for Research and Treatment of Cancer (EORTC) 3 and the German Cancer Society (GCS) 7 trials-and one cohort study of SRT. 4 Participants in all studies were of similar age, pre-and post-prostatectomy PSA, pathological stage and positive margin rate, but were slightly different in Gleason score, lymph node status and pre-RT PSA (Table 1) . In the trials, PSA recurrence rate was significantly higher with observation than ART. We estimated progression probabilities for our base-case analysis from the SWOG trial, because it was the only trial with follow-up long enough to detect a difference in the important long-term outcomes of metastasis and death. However, it should be noted that the more contemporary EORTC and GCS trials with shorter follow-up have similar 5-year PSA recurrence-free survival compared with SWOG: observation versus ART in SWOG was 45 versus 72%, in EORTC was 53 versus 74% and in GCS was 54 versus 72%. Thus, using the results from the SWOG study as the primary reference in our model is the more conservative approach (i.e. favors ART). Results from cohort studies of SRT 4, 5, [10] [11] [12] [13] [14] [15] [16] [17] can be used to estimate progression probabilities following SRT. We used data from Stephenson et al. 4 because it is the largest study by nearly 10-fold and reports results stratified by pre-RT PSA, which was essential to our model development. Importantly, a subset of 328 men in this study was treated at PSA p0.5 ng ml
À1
, which approximates the threshold for recurrence in the SWOG and EORTC studies (PSA 40.4 ng ml
).
Model development
We developed a state transition Markov model with 1-month cycle length to evaluate clinical outcomes after prostatectomy for a hypothetical cohort of 65-year-old men with locally advanced PC managed postoperatively with (1) ART or (2) initial observation plus SRT delivered at early PSA recurrence (PSA p0.5 ng ml
À1
). We assumed that men had PSA o0.4 ng ml À1 postoperatively and similar demographic and cancer characteristics to SWOG participants. Figure 1 provides an overview of the model (for complete model see Figure 2 ). Each month, ART-treated men faced a lower PSA recurrence risk than men on observation. 3, 6 For men on observation, we assumed that 75% would receive SRT at PSA recurrence, and varied this assumption in sensitivity analysis. Each month, men in each treatment arm could experience a post-RT PSA recurrence, either local or metastatic. The outcome of post-RT PSA recurrence was designed to be similar to an intent-to-treat analysis: for the 25% of men with PSA recurrence on observation who did not receive SRT, their initial PSA recurrence was considered as their post-RT PSA recurrence. Men with local recurrence faced a monthly risk of metastasis. All men with a post-RT PSA recurrence, whether local or metastatic, were managed Estimating model parameters Progression probabilities. We derived the annual probabilities of PSA recurrence with and without ART from the 10-year PSA recurrence-free survival probabilities reported in the SWOG trial (52% for ART, 28% for observation), 6 assuming constant rates over 10 years (Table 2) . 22 We derived the annual probabilities of PSA recurrence following SRT from the 10-year PSA recurrence-free probability in Stephenson et al. 4 For this variable, we included only the subset of participants who were treated at PSA (0.51-1.0 ng ml À1 ), to approximate the mean PSA at which SRT was delivered in the SWOG trial (0.7 ng ml À1 ). Metastasis was defined in the reference articles as bony or visceral metastases or extrapelvic nodal metastases. 3, 9 The cancer-specific mortality rate among men with metastases was derived from the 5-year relative survival probability for stage IV patients reported by the National Cancer Institute. 23 Model calibration. We used calibration to estimate transition probabilities that could not be directly calculated from the studies. 24 For instance, the 10-year risks of post-RT PSA recurrence and metastasis was known, but the risk of transition from a post-RT PSA recurrence to metastasis was unknown. Assuming all metastases were preceded by a PSA recurrence, the unknown transition probability (i.e., from post-RT PSA recurrence to metastases) was derived by varying its value over a plausible in order to match the model-predicted 10-year risk of metastasis with the observed risk. For all calibrations, we allowed 32% of the PSA recurrences on observation to receive SRT at an average PSA of 0.7 ng ml
, consistent with SWOG.
Adverse effects. We considered all possible combinations of four common adverse effects of radical prostatectomy and RT: erectile dysfunction, urinary obstruction, urinary incontinence and bowel dysfunction. We obtained the prevalence of these effects after radical prostatectomy, with and without RT, from the SWOG trial (Table 2) . 6, 8 To derive QALYs, we multiplied the probability of each unique health state by the health-related quality-oflife weight (utility) of that state ( Table 2 ). Utilities were drawn from Stewart et al. 25 who used standard gamble to elicit utilities for RT, metastatic disease, and several single and joint health states for a mixed sample of older men from the community and men recently diagnosed with PC. Similar utility values were obtained by other investigators using different methods. 26 We analyzed several models of the interaction between utilities for health states with a single complication and utilities for health states with multiple complications. The best-fit model (additive model) was used to impute the joint health state utilities not directly assessed in the Stewart study (see Supplementary Appendix A).
Cohort simulation
Having calibrated the model using conditions determined by SWOG: (1) 32% with PSA recurrence on observation received SRT; (2) SRT delivered at PSA 0.51-1.0 ng ml À1 and (3) background death rates drawn from the 1996 US Life Table 21 (time frame of SWOG trial), we then ran the model for a modern cohort, using the most recent life table (2004) (see ref. 27 ) and allowing 75% of men with PSA recurrence on observation to receive SRT at PSA p0.5 ng ml À1 (assuming some patients will be lost to follow-up or otherwise refuse SRT). We compared ART and observation with SRT on the basis of post-RT PSA recurrence-free survival, metastasis-free survival and overall survival at 10 years after surgery. We also projected QALY over 10 years, using utilities shown in Table 1 , to illustrate the trade-off between side effects and benefits of ART. The QALY analysis was repeated for a hypothetical 55-and 75-year-old man, inputting the different background death rates specific to these ages.
Sensitivity analysis
We performed sensitivity analyses for post-RT PSA recurrence by varying the probabilities of PSA recurrence on observation, after ART and after SRT. The first two probabilities were varied between half and twice their initial values. The third probability was varied over four probabilities of post-RT PSA recurrence in the Stephenson et al. 4 study when men were treated at PSA levels of p0.50, 0.51-1.00, 1.01-1.5 and 41.5 ng ml À1 . To account for the possibility that some men may not proceed with the recommended SRT, we also varied the probability of receiving SRT between 0 and 100%.
Additional one-way sensitivity analyses were carried out in which we varied the utility of the following health states over the range of 80-120% of their reference value: (1) no evidence of disease after RT, (2) post-RT PSA Clinical benefits of adjuvant radiotherapy SP Elliott et al recurrence and (3) metastatic disease. We did not vary the utility of radical prostatectomy because it was common to all patients, regardless of whether they received RT or not.
Results
Model calibration
Our model accurately predicted the 10-year PSA recurrence-free survival in both the observation (28%) and ART arms (52%) of the SWOG trial. It also accurately predicted metastasis-free survival (71%) and overall survival (74%) in the ART arm, after we adjusted the background death rate to 80% of the rate in the 1996 US Life Table ( i.e., representing a healthier trial population in terms of non-cancer mortality). Using the annual probability of progressing from PSA recurrence to metastatic disease, as estimated from the ART arm, our model underpredicted the incidence of metastases among men on observation. By increasing the annual Table. Overall, 75% of men with a PSA recurrence on observation actually receive indicated salvage RT (SRT). It is delivered at a PSA threshold of p0.5 ng ml
À1
. Note that the rate of progression from local recurrence to metastases is higher in the observation group than the ART group, but the rate of progression from metastases to death is equal in the two groups. Note that to decline indicated SRT places someone in a health state equivalent to a post-RT PSA recurrence. NED, no evidence of disease.
Clinical benefits of adjuvant radiotherapy SP Elliott et al probability of progression from PSA recurrence to metastatic disease from 5.7 to 6.5% in the observation arm, we were able to achieve the same 10-year metastasis-free survival as in the SWOG trial (61%).
Even with the correct 10-year metastasis-free survival, our model underpredicted deaths in the observation arm. To achieve the same 10-year overall survival probability as in the SWOG study (66%), we needed to either increase the annual probability of progression from metastasis to death in the observation arm to almost threefold that of the adjuvant arm (from 24 to 67%), or increase the background death rate to equal the rate in the 1996 US Life Table, which is 1.25-fold the rate for the adjuvant arm.
Cohort simulation
Using 2004 background death rates and assuming that 75% of men with PSA recurrence received SRT, our model demonstrated slightly lower 10-year PSA recurrence-free survival rates on observation versus ART (47 versus 52%; Table 3 ). We assumed that the probability of PSA recurrence progressing to metastases was higher in the observation patients but the annual probability of cancer death in those with metastatic disease was similar between strategies (Table 2 ). Under these assumptions we found that metastasis-free survival and overall survival were similar between strategies (Table 3) . With observation plus SRT, 28% of men similar to those in the SWOG trial would never experience PSA recurrence over 10 years and thus avoid SRT. A distribution of the expected time spent in each health state over 10 years is shown (Figure 3a) .
Expected QALYs
When the disutility of radiation was modeled, observation with SRT (given in 75% of PSA recurrences) 
Sensitivity analysis
Given a man has a PSA recurrence on observation, we varied between 0 and 100% the probability that he would receive SRT (Table 3 ). The resulting PSA recurrence-free survival varied from 28 to 53%, metastasis-free survival from 62 to 71%, overall survival from 68 to 74% and PC-specific deaths from 3 to 9%. Using three-way sensitivity analysis (Figure 4 ), we varied (1) the probability of PSA recurrence with observation, (2) the probability of PSA recurrence with ART and (3) the PSA prompting SRT. The outcome of interest was cumulative time, free of post-RT PSA recurrence over 10 years. As SRT is delayed until higher PSA values, ART becomes preferred over a wider range of effectiveness. Given the base-case values of probability of PSA recurrence with observation (9.5% per year) and ART (3.9% per year), the two strategies were equivalent when 75% of PSA recurrences on observation received SRT at PSA o0.5 ng ml À1 ; however, when SRT was delayed until reaching a higher PSA, ART was preferred. These findings were robust to variations in the annual probability of PSA recurrence to the values reported in the EORTC trial; 12.1% for observation and 5.8% for ART.
In one-way sensitivity analyses in which the utility of post-RT PSA recurrence and the utility of metastatic disease were varied and the outcome was QALYs over a 10-year time horizon, observation remained preferred over ART throughout the range of utility scores (results not shown). However, QALYs were sensitive to changes in the utility of RT. Specifically, the threshold value for the utility of no evidence of disease after RT was 0.85; at values above this, ART was preferred. In this analysis, the utility of no evidence of disease after radical prostatectomy was held constant at its reference value of 0.86.
Discussion
Our model predicted that for men with locally advanced PC who undergo radical prostatectomy, initial observation with early SRT (PSAp0.5 ng ml À1 ) is slightly less effective than ART for 10-year PSA recurrence-free survival, metastasis-free survival and overall survival. However, observation with early SRT confers similar Figure 4 Three-way sensitivity analysis on outcome of postradiotherapy PSA recurrence-free survival. To interpret, select a probability of recurrence after adjuvant radiation therapy (ART) (base case ¼ horizontal line at 3.9%) and on observation (base case ¼ vertical line at 9.5%). If the corresponding point on the graph is above the line representing one's predetermined PSA threshold at which salvage RT (SRT) is delivered (base case ¼ PSA o0.5 ng ml À1 ) then observation þ SRT is preferred. If it corresponds to a point below that line then ART is preferred. In the base-case analysis (represented by a 'star') ART is slightly preferred.
Clinical benefits of adjuvant radiotherapy SP Elliott et al or slightly better health-related quality of life to ART; 28% of men similar to those in the SWOG study avoid RT through 10 years and many more delay RT, thus avoiding or delaying the adverse effects of RT. Our model underestimates the real disutility of RT; we assumed RT toxicity to be of grade 1 or 2, whereas in the randomized trials grade 3 toxicity occurred in 4%. 3, 6 Furthermore, assessment of the late effects of RT was only available through 5 years. 3, 6 Including delayed complications would make ART less attractive.
Our model successfully projected the outcomes of PSA recurrence, metastasis and death as reported for the SWOG randomized trial of ART versus observation. An obstacle to modeling the SWOG study results, particularly for overall survival, was that the background death rate in SWOG's observation group appeared to be higher than in the ART group. Specifically, the number needed to treat to prevent one metastasis was 12.2 men, but the number needed to treat to prevent one death was only 9.1 men. 9 If the survival benefit of ART was achieved by reducing the number of metastases and thus cancer-specific deaths, then one would expect the number needed to treat to prevent one death to be more than the number needed to treat to prevent one metastasis. This raises the question of whether the observed survival benefit in the ART group was at least partially due to lower non-cancer-specific (i.e., background) death, despite randomization. We were able to account for this difference in survival in our model by either assigning a 67% annual probability of progression from metastasis to cancer death or a 1.25-fold higher background death rate in observation patients. Because a 67% annual death probability from metastatic PC is extremely high, we opted to use the higher background death rate for model calibration, then used equal background death rates for the cohort simulation. For all analyses, we applied a 24% probability of cancer death from metastases in both groups.
Decision models are limited by the assumptions used to build them. In general, ours is a conservative model, with assumptions constructed to bias against observation and SRT. Still, our model has limitations. We assumed that men on observation received SRT at earliest evidence of PSA recurrence (p0.5 ng ml
À1
). In reality, there will be variation in follow-up, and some men may progress beyond the point at which they would maximally benefit from SRT. 4 Decisions about a patient's commitment to intense surveillance may need to be made on an individual basis. Although our results were robust when assuming that 75% of the men needing SRT actually received it, when that number dropped to 50%, ART was preferred. If more than 75% of men with a PSA recurrence on observation can be expected to complete SRT, then observation becomes an even more attractive option. Such a high SRT capture rate might be achievable in a trial setting; however, in community-based registries, the frequency of SRT in men with a PSA recurrence has been as low as 11% in the early 1990s and as high as 32% in 2000-2004. 28, 29 Thus, the ability to follow an observation protocol and willingness to proceed with SRT should be integral to selecting observation versus ART.
There are limitations to the external validity of the results. First, roughly a third of the men in the SWOG and EORTC trials had a persistently elevated PSA postprostatectomy, which could represent residual cancer.
Second, contemporary men have on average lower grade, stage and PSA than men in the era of the SWOG and EORTC trials. 2 Although, the more contemporary GCS trial in which all men had a negative postoperative PSA still had a probability of PSA recurrence similar to that in the SWOG and EORTC trials, the GCS men had high risk cancer (8% had T4 disease). A modern patient with only one of the features of locally advanced PC (extracapsular extension, PSA or seminal vesicle invasion) will typically have a 10-year PSA recurrencefree survival of 70-80%, compared with the 28% used in this model. Third, men in the SWOG trial received SRT at higher PSA thresholds than those used currently. In summary, all three of these features that contrast with current practice (lower risk patients, a negative postoperative PSA and earlier SRT delivery) would only lend stronger support for initial observation in the modern era.
Other limitations bear mention. The negative impact of RT on QALYs significantly affects the interpretation of our model. As utilities are subjective, future investigations should incorporate sensitivity analyses around the utility values in the model. Our findings should only be applied to men with disease similar to the average participant in the reference cohorts, and not men with metastatic disease, T4 disease or PSA X0.4 after prostatectomy. In subset analyses, the benefits of adjuvant and SRT were experienced by select high-risk patients; 9, 17 however, the reference studies lacked sufficient detail to design a model that accommodates factors predictive of individual response to therapy. We model results for a cohort of 65-year-old men. When varying the background death rate down to that of a 55-year-old man or up to that of a 75-year-old man, QALYs remained higher with observation than ART. In sensitivity analysis, we demonstrate that ART is preferred over observation for the outcome of 10-year QALYs only when the utility of RT is nearly equal to the utility of observation (0.85 versus 0.86, respectively). In practical terms, this means that ART would be preferred over observation only if radiation was essentially side-effect-free or if men placed little value on the additional risk of those radiation side effects. Indeed, modern radiation techniques may yield different results from those seen in this study; specifically, rectal complications are lower but urinary complications may be higher with intensity-modulated RT than 3-D conformal RT. 30 Although our sensitivity analyses show our findings to be robust over a wide range of ART and SRT effectiveness, the optimum model would allow the clinician to input an individual's disease characteristics and arrive at a preferred treatment strategy. A combination of our model with input probabilities from nomograms such as the Kattan nomogram is intriguing area for future research. 2 In our model, ART showed slightly better clinical outcomes compared with observation plus SRT in terms of post-RT PSA recurrence-free survival, metastasis-free survival and overall survival. When the adverse effects of RT were included in the decision model, observation plus SRT became the preferred treatment. These results were highly dependent on delivering SRT early (at PSA p0.5 ng ml À1 ) and in X75% of observed patients with a PSA recurrence. This model can inform physicianpatient treatment discussions as we await the results of randomized clinical studies.
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